Blog - Dexcom News
How Dexcom Integrates With the mylife YpsoPump
If you’re living with diabetes and take insulin as part of your care, a continuous glucose monitoring (CGM) system is a helpful way to make treatment decisions and gauge your dosage without regular finger pricks.* A more convenient alternative is to use an insulin pump that connects with your CGM system to automate insulin delivery.
Automated insulin delivery (AID) can relieve you from constant blood glucose monitoring and remove some of the stress that comes with diabetes management. It also frees up more of your attention and energy so that you can focus on what you love doing every day.
There are several insulin pumps available that can integrate with Dexcom Continuous Glucose Monitoring (CGM) Systems. If you use the Dexcom G6 CGM System, the mylife YpsoPump might be a good option.
What is automated insulin delivery (AID) and why use it?
If you’ve researched insulin treatment, you may have heard about automated insulin delivery systems—sometimes called an artificial pancreas or a hybrid closed loop (HCL) system. AID systems aim to mimic insulin regulation, similar to that of a pancreas, by combining three technologies: A CGM system, an insulin pump, and an algorithm. The CGM system measures and predicts your glucose levels. The algorithm then uses the CGM data to determine your insulin needs and “tells” the pump how much to deliver.
With this approach, you don’t need to inject insulin manually as often or spend time taking routine finger prick tests.* An adaptive AID system can give you much more freedom to live your life without sacrificing peace of mind. It has also been shown to increase your time in range,1,2 which is an indicator for glycaemic control. A better glycaemic control is shown to reduce the risk of long-term complications.3,4
What is the mylife YpsoPump?
The mylife YpsoPump is an insulin pump that can be used on its own or combined with a CGM system, like Dexcom CGM, and an algorithm for automated insulin delivery. To do this, you’ll need the mylife CamAPS FX app, which is the algorithm that determines the correct insulin dosage based on your CGM readings.
How the mylife YpsoPump - integrates with Dexcom
If you use Dexcom G6, combining it with the mylife YpsoPump can be a great way to alleviate the daily effort required to manage your glucose levels. Here’s how the integration works:
- You connect the mylife Cam APS FX app to your Dexcom G6 sensor and the mylife YpsoPump.
- Dexcom G6 sends your glucose readings to the Cam APS FX app up to every five minutes.
- Using those readings, the app tells your pump how much insulin to deliver to prevent glucose highs and lows.
The system constantly learns and adapts, stabilising glucose levels based on how your lifestyle habits, like diet and exercise, affect them. You can also continue using your Dexcom G6 app to check your glucose trends, get alerts for highs and lows, and share important data with your loved ones and diabetes care team.
How the mylife YpsoPump can simplify diabetes management
The mylife YpsoPump is designed with convenience and flexibility in mind to fit seamlessly into your life.
1. Discreet and user-friendly
The mylife YpsoPump might be a good option if you want a “barely there” device that allows you to use necessary functions quickly and get on with your day. The pump is small, lightweight, and uses a 360° tube connector that moves with you, even when you’re active. The pump has a minimal learning curve, with a simple touchscreen that has intuitive icons. You can also use pre-filled cartridges or a self-filling reservoir with the pump—whichever works best for you.
2. Approved for ages two and over
If you look after a child who is living with diabetes, AID systems can increase their time in range†,5 and give you added peace of mind as a caregiver. Research suggests that when young children use this method of taking insulin, parents and caregivers tend to experience a reduced burden of diabetes management, less worry, and better quality sleep.6 When combined with Dexcom G6 and the mylife Cam APS FX app, the mylife YpsoPump offers the only approved AID system for ages two and older.
3. Flexible and adaptive to your needs
Everyone has a unique lifestyle, and you may experience changing routines that affect your glucose levels. An AID system with the mylife YpsoPump can help you spend less time adjusting to these changes in your insulin requirements. This is because the system is self-learning, using your Dexcom CGM readings and an algorithm to adjust insulin delivery based on your habits and what your body needs. For example, if you tend to under-dose your meal bolus, the system will recognise this pattern and adapt to prevent highs and lows. If you know your insulin requirements are likely to change—you’re about to go for a brisk walk, for example—you can also use the “Boost” or “Ease-off” modes to quickly adjust your glucose target as necessary.
4. Options for meal management and varied glucose targets
You and your diabetes care team may find that your glucose targets vary throughout the day. The pump’s settings allow you to set different targets in 30-minute segments so you can stay present without needing to worry about making dosage adjustments. There’s also a slowly absorbed meal feature that delivers extra insulin over a few hours. This makes insulin delivery convenient if you plan on eating food that digests slowly, like high-fat or protein-rich meals.
5. Designed to support pregnant users
Insulin requirements can change during pregnancy,7 while diabetes may increase the risk of complications to the pregnancy or the developing baby.8 Increasing your time in range can help support a healthy pregnancy. Automated insulin delivery with mylife YpsoPump is safe to use during pregnancy and childbirth and has been shown to effectively control glucose levels in pregnant women living with type 1 diabetes.9
Learn more about using mylife YpsoPump with Dexcom G6
An automated insulin delivery system can empower you to live your best life while keeping your glucose levels in check. By combining the mylife YpsoPump with Dexcom G6, you can take back your time and energy with an AID system that adapts to you and your lifestyle—and not the other way around.
* Finger pricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
† The use of CamAPS FX in young children aged 1 to 7 years documented clinically and statistically an increase in time in target glucose range by 9% without increasing time in hypoglycaemia below 3.9mmol/L.
1 Peacock, S et al. A Systematic Review of Commercial Hybrid ClosedLoop Automated Insulin Delivery Systems. Diabetes Ther 2023;14(5):839-855.
2 Alwan H, et al. Real-World Evidence Analysis of a Hybrid Closed-Loop System. J Diabetes Sci Technol. 2023 Jul 8:19322968231185348.
3 DCCT and EDIC Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016 May;39(5):686-93.
4 Beck RW, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400-405.
5 Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022 Jan;386(3):209-219.
6 Musolino G, et al. Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019;20(6):794-799.
7 Type 1 Diabetes and Pregnancy. Centers for Disease Control and Prevention. Accessed February 2024. https://www.cdc.gov/diabetes/library/features/type-1-and-pregnancy.html.
8 Planning For A Pregnancy When You Have Diabetes. Diabetes UK. Accessed February 2024. https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/pregnancy.
9 Lee, et al. Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes. N Engl J Med. 2023 Oct 26;389(17):1566-1578.
† The use of CamAPS FX in young children aged 1 to 7 years documented clinically and statistically an increase in time in target glucose range by 9% without increasing time in hypoglycaemia below 3.9mmol/L.
1 Peacock, S et al. A Systematic Review of Commercial Hybrid ClosedLoop Automated Insulin Delivery Systems. Diabetes Ther 2023;14(5):839-855.
2 Alwan H, et al. Real-World Evidence Analysis of a Hybrid Closed-Loop System. J Diabetes Sci Technol. 2023 Jul 8:19322968231185348.
3 DCCT and EDIC Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016 May;39(5):686-93.
4 Beck RW, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400-405.
5 Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 2022 Jan;386(3):209-219.
6 Musolino G, et al. Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019;20(6):794-799.
7 Type 1 Diabetes and Pregnancy. Centers for Disease Control and Prevention. Accessed February 2024. https://www.cdc.gov/diabetes/library/features/type-1-and-pregnancy.html.
8 Planning For A Pregnancy When You Have Diabetes. Diabetes UK. Accessed February 2024. https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/pregnancy.
9 Lee, et al. Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes. N Engl J Med. 2023 Oct 26;389(17):1566-1578.